Background Germline pathogenic variants (gPVs) in <i>BRCA1</i>, <i>BRCA2</i>, and <i>CHEK2</i> are well‐established cancer predisposition factors of prostate cancer. This evidence concerns the gene BRCA2 and prostate carcinoma.